Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

702

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Ovarian CancerBreast CancerPancreatic CancerProstate CancerAdditional Indications Below for Module 4 and 5Non-small Cell Lung CancerColorectal CancerBladder CancerGastric CancerBiliary CancerCervical CancerEndometrial CancerSmall Cell Lung Cancer Only in Module 5
Interventions
DRUG

AZD5305

Oral PARP inhibitor

DRUG

Paclitaxel

IV Anti-microtubule agent

DRUG

Carboplatin

IV Platinum chemotherapeutic

DRUG

T- Dxd

IV Antibody-drug conjugate

DRUG

Dato-DXd

IV Antibody-drug conjugate

DRUG

Camizestrant

Oral SERD Molecule

Trial Locations (68)

1062

Research Site, Budapest

1082

Research Site, Budapest

1122

Research Site, Budapest

3000

Research Site, Melbourne

3084

Research Site, Heidelberg

10021

Research Site, New York

15006

Research Site, Prague

20132

Research Site, Milan

20141

Research Site, Milan

28040

Research Site, Madrid

28041

Research Site, Madrid

28050

Research Site, Madrid

28223

Research Site, Pozuelo de Alarcón

29010

Research Site, Málaga

35128

Research Site, Padua

41013

Research Site, Seville

41125

Research Site, Modena

58013

Research Site, Chernivtsі

73104

Research Site, Oklahoma City

76018

Research Site, Ivano-Frankivsk

77030

Research Site, Houston

80131

Research Site, Napoli

88000

Research Site, Uzhhorod

100142

Research Site, Beijing

111123

Research Site, Moscow

115478

Research Site, Moscow

117997

Research Site, Moscow

130021

Research Site, Changchun

143442

Research Site, Moscow

150081

Research Site, Harbin

200025

Research Site, Shanghai

200032

Research Site, Shanghai

272029

Research Site, Jining

400030

Research Site, Chongqing

410013

Research Site, Changsha

430079

Research Site, Wuhan

510060

Research Site, Guangzhou

610041

Research Site, Chengdu

710061

Research Site, Xi'an

02114

Research Site, Boston

02215

Research Site, Boston

V5Z 1K1

Research Site, Vancouver

M5G 2M9

Research Site, Toronto

H2X 0A9

Research Site, Montreal

H3T 1E2

Research Site, Montreal

Unknown

Research Site, Shandong

030001

Research Site, Taiyuan

656 53

Research Site, Brno

00168

Research Site, Roma

104-0045

Research Site, Chūōku

135-8550

Research Site, Kōtoku

85-796

Research Site, Bydgoszcz

80-214

Research Site, Gdansk

81-519

Research Site, Gdynia

72-003

Research Site, Grzepnica

90-302

Research Site, Lodz

87-100

Research Site, Torun

02-781

Research Site, Warsaw

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

08035

Research Site, Barcelona

03022

Research Site, Kyiv

CB2 0QQ

Research Site, Cambridge

M20 4BX

Research Site, Manchester

OX3 7LE

Research Site, Oxford

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY